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Executive Summary deutsch 
 
Ziel:  
Empirisch belegte und bewährte Interventionen im Bereich der Tabakprävention und der 
Entwöhnungsbehandlung wurden auf ihre Effektivität und Kosteneffektivität bei der 
Reduktion Tabak-bedingter Mortalität geprüft und verglichen.  Dadurch soll ermöglicht 
werden, Präventionsstrategien zukünftig zu bündeln und einen maximalen Effekt bei 
gegebenem Ressourcenaufwand zu erzielen. 
 
Methodik:  
Epidemiologische Analyse (inklusive Sensitivitätsanalysen) der durch ausgewählte 
Interventionen erzielbaren Effekte bei der Reduktion Tabak-bedingter Mortalität einerseits 
und der infolge Tabakkonsums verlorenen Lebensjahre und Krankheitslast andererseits für 
die erwachsene Gesamtbevölkerung der Schweiz für das Jahr 2002, jeweils getrennt nach 
von Aktiv- versus Passivrauchen bedingter Mortalität.  Ökonomische Analyse der 
Kosteneffektivität der genannten Interventionen mit zwei Kriterien: Anzahl der Rauchenden 
und Tabak-bedingte Mortalität. 
 
Zielkriterien:  
a) Tabak-bedingte Mortalität – getrennt nach Aktiv- und Passivrauchtoten; 
b) durch Tabakkonsum verlorene Lebensjahre (wiederum getrennt nach Aktiv- und 
Passivrauch bedingten verlorenen Lebensjahren); 
c) Tabak bedingte Krankheitsbelastung in DALYs (disability-adjusted life years). 
 
Alle Indikatoren wurden ermittelt anhand zweier Tracer-Diagnosen (Lungenkrebs 
(ICD 9 162; ICD 10 C33-C34) und koronare Herzkrankheit (ICD 9 410-414; ICD 10 
I20-I25)) für das Jahr 2002.  Zusätzlich wurden die gesamten rauchbedingten 
Gesundheitsschäden, d.h. die gesamte Morbiditäts- und Mortalitätslast, die durch 
Rauchen verursacht wurde, berechnet. 
 
Interventionen:  
Es wurden schweizerischen ExpertInnen verschiedene Interventionsstrategien zur 
Auswahl hinsichtlich Ihrer Anwendung in der Schweiz vorgelegt, die dann in Ihrer 
Wirkung speziell für die Schweiz modelliert wurden (sowohl allein für sich wie in 
Kombination): 
a) Verhältnisprävention: 
¾ Preiserhöhungen, zum Beispiel durch Besteuerung 
¾ Rauchverbote auf öffentlichen Plätzen 
¾ Arbeitsplatz-bezogene Interventionen 
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b) Verhaltensprävention & Therapie: 
¾ Kurzinterventionen durch individuelle, nichtärztliche Beratung 
¾ Substitutionstherapien (Nicotine Replacement Therapy) 
¾ Ärztliche Beratung 
 
Bestimmung der quantitativen Auswirkungen der verschiedenen 
Interventionen:  
Aus den jüngst verfügbaren Meta-Analysen wurde jeweils die Effektivität jeder 
Massnahme bestimmt. 
 
Datengrundlagen: 
Zielkriterien: Mortalitäts- und Morbiditätsdaten wurden von der WHO bezogen; die 
epidemiologischen Daten zum Tabakkonsum in der Schweiz wurden der 
Schweizerischen Gesundheitsbefragung (SGB) entnommen und von Dr. G. Gmel 
(SFA) aufbereitet; die Relativen Risiken für Raucher und Ex-Raucher wurden aus 
epidemiologischen Meta-Analysen übernommen, und die Effekte des 
Passivrauchens wurden indirekt ermittelt. 
 
Interventionen:  Die Effektgrössen für die Massnahmen wurden soweit möglich der 
Cochrane Database entnommen, weil dadurch die aktuell höchstmögliche Präzision 
der Schätzungen erreicht wird. 
 
Resultate: 
Insgesamt ergaben sich für das Jahr 2002 in der Schweiz je nach Annahmen hinsichtlich 
Tabak-bedingten Krankheiten und den entspechenden Relativen Risiken zwischen 6’175 
und 7'300 Tabak-bedingte Sterbefälle.  Details sind folgender Tabelle zu entnehmen. 
 
Schätzung rauchbedingter (inklusive Passivrauchen) Todesfälle in der Schweiz 2002 
(Erwachsene 20 Jahre und älter) 
 Männer Frauen Gesamt % an allen Todesfällen 
Aktivrauchbedingte Todesfälle (English et al.^) 4’194 1’843 6’037 9.9%
Aktivrauchbedingte Todesfälle (CPS II**) 5’339 1’663 7’002 11.5%
Passivrauchbedingte Todesfälle (English et al.*) 91 46 138 0.2%
Passivauchbedingte Todesfälle (CPS II**) 116 41 160 0.3%
Tabak-bedingte Todesfälle gesamt (English et al.*) 4’286 1’888 6’175 10.1%
Tabak-bedingte Todesfälle gesamt (CPS II**) 5’455 1’704 7’162 11.8%
Tabak-bedingte Todesfälle gesamt (indirekte Methode***) 5’600 1’800 7’300 12.0%
Todesfälle basieren auf attributiven Fraktionen und weisen Nachkommastellen auf. 
* RR aus (English et al., 1995) (siehe Text) 
** RR aus der CPS II Studie (siehe Text) 
*** indirekte Schätzung basierend auf Lungenkrebstodesraten; Daten aus 2000 und in der 
Originalveröffentlichung nur auf 100 Tote genau angegeben (Peto et al., 1992; Peto et al., 
2006) siehe Text 
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Die beiden für Rauchen charakteristischen Diagnosen (Tracer-Diagnosen) Lungenkrebs und 
ischämische Herzkrankheiten machen etwas mehr als die Hälfte aller rauchbedingten 
Todesfälle aus.  Basierend auf einer konservativen Schätzung mit den Annahmen von 
English und Kollegen (English et al., 1995) verloren Raucher in der Schweiz im Jahre 2002 
42’902 Lebensjahre frühzeitig (12.2% der gesamten YLLs – years of life lost - in der 
Schweiz).  Die Gesamtlast unter Einbeziehung von Passivrauchen betrug 43'871 YLLs 
(12.5% der gesamten YLLs).   Die Tabak-bedingte Krankheitslast betrug 59’273 DALYs  
(disability adjusted life years; 7.4% der gesamten Krankheitslast in der Schweiz), ohne 
Passivrauchlast, und 60’617 DALYS insgesamt (7.6% ). 
 
Die untersuchten Interventionen resultierten in jährlichen Prävalenzminderungen an 
RaucherInnen zwischen 0% und 1.4% in der Allgemeinbevölkerung (Reduktionen von 0% 
bis 6.0% unter RaucherInnen), gleichbedeutend mit einer Reduzierung um maximal ca. 
85'000 RaucherInnen in der Schweiz.  Betrachtet man die Tabak-bedingten Todesfälle, so 
könnten diese um bis zu 85 Todesfälle jährlich ab sofort reduziert werden. Bei den 
genannten Zahlen ist zu bedenken, dass die gewählten Interventionsszenarien realistisch in 
dem Sinne waren, dass sie tatsächliche Chancen auf Durchsetzbarkeit in der Schweiz 
haben.  Drastischere Steuererhöhungen würden in deutlich höheren Prävalenz- (z.B. 20% 
der RaucherInnen bei Verdoppelung des Preises) und Mortalitätsminderungen resultieren 
(bei Verdoppelung des Preises Reduktion der Tabak-bedingten Todesfälle um 272). 
 
Hinsichtlich der Kosteneffektivität zeigt sich deutlich, dass die beiden verhältnispräventiven 
Massnahmen Steuererhöhung und Rauchverbot an öffentlichen Plätzen kosteneffektiver 
sind als alle individuell-basierten Interventionen wie Beratung und Therapie.  Die Kosten für 
eine 1%-Reduktion der Raucheranzahl in der Schweiz belaufen sich dabei zwischen CHF 
140'000.- (Verdoppelung des Preises via Steuererhöhung) und über CHF 80 Millionen (bei 
flächendeckender Anwendung von ärztlich verordneter Substitutionstherapie). 
 
Relevanz: 
Rauchbedingte Todesfälle und - Krankheitslast zählen zu den wichtigsten Public Health 
Problemen in der Schweiz. Es existieren effektive Interventionen, die auch in der Scheiz 
durchgeführt werden könnnen. Allerdings bringen diese Interventionen keine plötzlichen und 
durchschlagenden Erfolge hinsichtlich der RaucherInnenprävalenz und rauchbedingter 
Krankheitslast.  Es ist zu bedenken, ob nicht drastischere Massnahmen der Tabakkontrolle 
angestrebt werden sollten.  
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Executive Summary English 
 
Objectives:  
To compare evidence-based interventions for tobacco control and treatment of tobacco 
dependence with respect to their cost-effectiveness.  The aim of this cost-effectiveness 
analysis is to inform preventive strategies in Switzerland and obtain an optimal outcome with 
given resources. 
 
Methods:  
Economic analysis based on epidemiologic analyses of effects resulting from tobacco 
control interventions.  Various sensitivity analyses were conducted both for the 
epidemiological and the economic part.  All effects were calculated based on the year 2002; 
outcome criteria included number of smokers in Switzerland and different health indicators. 
 
Main outcome criteria:  
a) Smoking-attributable mortality – including calculation of the effect of 
environmental tobacco smoke (ETS); 
b) Smoking-attributable years of life lost – again also including ETS; 
c) Smoking-attributable burden of disease including ETS in DALYs (disability-
adjusted life years). 
 
All Indicators were also calculated for all smoking-attributable diagnoses and for two 
tracer diagnoses (Lung cancer (ICD 9 162; ICD 10 C33-C34) and ischaemic heart 
disease (ICD 9 410-414; ICD 10 I20-I25)), again for the year 2002.   
 
Interventions:  
A comprehensive set of different types of interventions were given to local experts to 
select the interventions to be modeled, taken into consideration especially the 
effectiveness and feasibility for Switzerland.  The following interventions were 
selected for further analyses, both alone and in combination:  
Public policy interventions: 
¾ Price increase 
¾ Interventions for preventing tobacco smoking in public places 
¾ Workplace interventions for smoking cessation  
Interventions focusing on individual behavioural change (counselling, brief 
advice, therapy): 
¾ Individual behavioural counselling for smoking cessation. 
¾ Nicotine replacement therapy for smoking cessation 
¾ Physician advice for smoking cessation 
 
Estimation of the effect sizes:  
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We used comprehensive meta-analyses to quantify the effect of different 
interventions. 
 
Data sources: 
All disease-specific outcome data (i.e. deaths, years of life lost, DALYs) were 
obtained from the WHO, the exposure data on tobacco consumption were taken from 
the Swiss Health Survey (data analyses from Dr. G. Gmel - SIPA).  Relative Risks 
were taken from epidemiological meta-analyses, and the effects of ETS were 
estimated based on Canadian analyses. 
 
The effect sizes for interventions were taken from the Cochrane Database whenever 
possible to secure comparability and high validity. 
 
Results: 
Overall, we estimate that between 6,175 and 7,300 adult Swiss were killed by tobacco in the 
year 2002.  The details can be seen in the following overview Table: 
 
Estimates of smoking-attributable adult deaths in Switzerland 2002 including ETS 
 Men Women Total % of all deaths 
Total smoking-attributable deaths from own smoking  
(English et al., 1995 direct method) 4,194 1,843 6,037 9.9%
Total smoking-attributable deaths from own smoking  
(CPS II direct method) 5,339 1,663 7,002 11.5%
ETS (English et al., 1995 direct method) 91 46 138 0.2%
ETS (CPS II direct method) 116 41 160 0.3%
Total smoking-attributable deaths  
(English et al., 1995) - direct method 4,286 1,888 6,175 10.1%
Total smoking-attributable deaths 
(CPS II) – direct method 5,455 1,704 7,162 11.8%
Total smoking-attributable deaths  
(Peto et al., 1992; Peto et al., 2006) – indirect method 5,600 1,800 7,300 12.0%
Numbers may not add up because of rounding (all numbers are based on attributable fractions and 
thus have decimals); the numbers of Peto et al. (2006) were given in 100s in the original publication. 
 
The two tracer diagnoses lung cancer and IHD comprise slightly more than 50% of the all 
smoking-attributable mortality.  Based on the most conservative estimate (English et al., 
1995) Swiss smokers accounted for 42’902 years of life lost (YLLs; 12.2% of all YLLs in 
Switzerland in 2002).  Including ETS the smoking-attributable YLLs amounted to 43'871 
YLLs (12.5% of all YLLs).  Smoking-attributable burden of disease in 2002 was estimated to 
be 59’273 DALYs (7.4% of all DALYs) without ETS and 60’617 DALYS including ETS (7.6% 
of all DALYs). 
Cost effectiveness tobacco  7 
 
The examined interventions resulted in yearly prevalence reductions between 0% and 1.4% 
relative to the general population and between 0% and 6% among smokers, corresponding 
to a reduction of up to 85,000 smokers.  The interventions could reduced yearly smoking-
attributable mortality by about 85 deaths per year.  When evaluating this figures, it should be 
kept in mind, that the chosen interventions were realistic in the sense, that they could be 
easily implemented in Switzerland.  More drastic taxation increases resulting in 50% 
respectively 100% increases of price for cigarettes would result in more pronounced effects.  
For instance, a 100% increase of prices would result in 20% reduction of smoking 
prevalence and 272 deaths saved per year. 
 
With respect to cost-effectiveness, public policy measures such as even minor increases in 
taxation or ban of smoking in public places clearly are more cost-effective than individual 
counselling or therapy.  The costs for reduction of smoking prevalence by 1% vary between 
CHF 140,000 (drastic taxation increases which double the price for cigarettes) and more 
than CHF 80 millions, if prevalence is reduced by prescribed nicotine replacement therapy 
alone. 
 
Relevance: 
Smoking-attributable mortality and burden of disease is a major public health problem in 
Switzerland.  There are effective evidence-based interventions which could also be 
implemented here.  However, these interventions will bring only gradual improvements in 
reducing prevalence of smoking and smoking-attributable burden of disease.  Given this 
situation more drastic measures than currently contemplated should be considered. 
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Introduction 
Tobacco use is responsible for high levels of mortality and morbidity.  Smoking causes 
substantially increased risk of mortality from lung cancer, upper aerodigestive cancer, 
several other cancers, heart disease, stroke, chronic respiratory disease and a range of 
other medical causes (USDHHS: U.S.Department of Health and Human Services, 2004).  In 
the developed world in the year 2000, smoking was reported to be the risk factor with the 
largest attributable mortality and attributable disability adjusted life years (DALYS) by the 
(WHO, 2002); overall 12.2% of all DALYS were attributed to this risk factor. 
 
Given the extent of tobacco-attributable disease burden described above, tobacco control 
measures have gained more and more importance.  Though there is considerable political 
and public for such measures (but see Cornuz et al., 1996, for Switzerland), resources are 
limited, even in a rich country like Switzerland.  Thus, cost-effective tobacco control 
measures are important in further reducing the burden of tobacco smoking.  Economic 
analyses are key to identifying and implementing such cost-effective measures (for general 
considerations and definitions see Drummond et al., 1997; Drummond & McGuire, 2001; for 
the field of substance abuse especially in German-speaking countries see Rehm, 1999; 
Rehm et al., 2004a; Tretter et al., 2004). 
 
This contribution will provide epidemiologic and economic analyses of the effects of different 
interventions to reduce smoking-attributable burden in Switzerland.  We will not restrict 
ourselves to the more traditional field of cost-effectiveness of different treatment options 
(e.g. Cornuz et al., 2006), but will include cost-effectiveness of preventive efforts, including 
public policy interventions such as taxation increases or a ban of smoking in public spaces 
(see generally Bryant et al., 1997).  We can only hope that our analyses can influence 
decision making about tobacco control in Switzerland. 
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Methods 
Selection of interventions 
The selection of interventions was undertaken in two steps: 
• Collection of evidence for most common interventions via a search of meta-analyses 
with special emphasis on Cochrane reviews; 
• Expert consultation to select the best fitting types of interventions for Switzerland. 
 
 
Collection of evidence for most common interventions 
The following systematic reviews were found with respect to effectiveness of smoking-
related interventions in the Cochrane database (all links accessed in February 2006; for a 
more general short overview on the most utilized tobacco control interventions and their 
coverage see Jha et al., 2006): 
 
Acupuncture for smoking cessation http://www.cochrane.org/reviews/en/ab000009.html 
Antidepressants for smoking 
cessation http://www.cochrane.org/reviews/en/ab000031.html 
Anxiolytics for smoking cessation http://www.cochrane.org/reviews/en/ab002849.html 
Aversive smoking for smoking 
cessation http://www.cochrane.org/reviews/en/ab000546.html 
Clonidine for smoking cessation http://www.cochrane.org/reviews/en/ab000058.html 
Community interventions for 
preventing smoking  
http://www.cochrane.org/reviews/en/ab001291.html 
http://www.cochrane.org/reviews/en/ab001745.html 
Community pharmacy personnel 
interventions for smoking cessation http://www.cochrane.org/reviews/en/ab003698.html 
Competitions and incentives for 
smoking cessation http://www.cochrane.org/reviews/en/ab004307.html 
Enhancing partner support to 
improve smoking cessation http://www.cochrane.org/reviews/en/ab002928.html 
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Exercise interventions for smoking 
cessation http://www.cochrane.org/reviews/en/ab002295.html 
Family and carer smoking control 
programmes for reducing children’s 
exposure to environmental tobacco 
smoke 
http://www.cochrane.org/reviews/en/ab001746.html 
Group behaviour therapy 
programmes for smoking cessation http://www.cochrane.org/reviews/en/ab001007.html 
Healthcare financing systems for 
increasing the use of tobacco 
dependence treatment 
http://www.cochrane.org/reviews/en/ab004305.html 
Hypnotherapy for smoking 
cessation http://www.cochrane.org/reviews/en/ab001008.html 
Individual behavioural counselling 
for smoking cessation http://www.cochrane.org/reviews/en/ab001292.html 
Interventions for preoperative 
smoking cessation http://www.cochrane.org/reviews/en/ab002294.html 
Interventions for preventing 
tobacco sales to minors http://www.cochrane.org/reviews/en/ab001497.html 
Interventions for preventing 
tobacco smoking in public places http://www.cochrane.org/reviews/en/ab001294.html 
Interventions for smokeless 
tobacco use cessation http://www.cochrane.org/reviews/en/ab004306.html 
Interventions for smoking cessation 
in hospitalised patients http://www.cochrane.org/reviews/en/ab001837.html 
Lobeline for smoking cessation http://www.cochrane.org/reviews/en/ab000124.html 
Mass media interventions for 
preventing smoking in young 
people 
http://www.cochrane.org/reviews/en/ab001006.html 
Mecamylamine (a nicotine 
antagonist) for smoking cessation http://www.cochrane.org/reviews/en/ab001009.html 
Nicotine replacement therapy for 
smoking cessation http://www.cochrane.org/reviews/en/ab000146.html 
Nursing interventions for smoking 
cessation http://www.cochrane.org/reviews/en/ab001188.html 
Opioid antagonists for smoking 
cessation http://www.cochrane.org/reviews/en/ab003086.html 
Physician advice for smoking 
cessation http://www.cochrane.org/reviews/en/ab000165.html 
Quit and Win contests for smoking 
cessation http://www.cochrane.org/reviews/en/ab004986.html 
Relapse prevention interventions http://www.cochrane.org/reviews/en/ab003999.html 
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for smoking cessation 
School-based programmes for 
preventing smoking http://www.cochrane.org/reviews/en/ab001293.html 
Self-help interventions for smoking 
cessation http://www.cochrane.org/reviews/en/ab001118.html 
Silver acetate for smoking 
cessation http://www.cochrane.org/reviews/en/ab000191.html 
Telephone counselling for smoking 
cessation http://www.cochrane.org/reviews/en/ab002850.html 
Training health professionals in 
smoking cessation http://www.cochrane.org/reviews/en/ab000214.html 
Workplace interventions for 
smoking cessation http://www.cochrane.org/reviews/en/ab003440.html 
 
 
Expert consultation 
Five experts were contacted with a structured questionnaire to solicit answers as to which 
interventions would best fit for Switzerland based on importance with respect to reduce 
tobacco-attributable harm (see Appendix 1 for details): 
• J. Cornuz, MD – Medical director (Medecin-chef), Policlinique Médicale Universitaire, 
Lausanne, a university affiliated outpatient clinic; 
• M. Graf – Director of the Swiss Institute for the Prevention of Alcohol and Drugs 
Problems (SFA/ISPA/SIPA), Lausanne, one of the two internationally renowned 
addiction research institutes in Switzerland;  
• K. Klingler, MD – Medical Director of The Hirslanden Pneumology Center, Zurich, a 
private hospital; 
• E. Scheuer, MD – Director of „Rauchersprechstunde“ 
(www.rauchersprechstunde.ch), a private organization, which offers individually 
tailored behavioural smoking cessations programs; 
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• C. Schwendimann – Director of „Züri Rauchfrei“ („Zurich Smokefree“; 
http://www.zurismokefree.ch ), a cantonal agency for tobacco control and prevention. 
 
 
Interventions selected 
The following interventions were selected based on the feedback of the experts: 
 
Public policy interventions: 
Price increase 
http://scholar.google.com/scholar%3Fq%3Dauthor:%22Ranson%22+intitle:%22The+effectiv
eness+and+cost-effectiveness+of+price+...%22+%26hl%3Dde%26lr%3D%26ie%3DUTF-
8%26oi%3Dscholarr 
(last accessed: 12-29-06) 
 
Interventions for preventing tobacco smoking in public places 
http://www.cochrane.org/reviews/en/ab001294.html 
(last accessed: 12-29-06) 
 
Comprehensive workplace interventions for smoking cessation  
http://www.cochrane.org/reviews/en/ab003440.html 
(last accessed: 12-29-06) 
 
Interventions focusing on individual behavioural change (counselling, brief advice, 
therapy): 
Individual behavioural counselling for smoking cessation. 
http://www.cochrane.org/reviews/en/ab001292.html 
(last accessed: 01-03-07) 
 
Nicotine replacement therapy for smoking cessation 
http://www.cochrane.org/reviews/en/ab000146.html 
(last accessed: 01-03-07) 
 
Physician advice for smoking cessation 
http://www.cochrane.org/reviews/en/ab000165.html 
(last accessed: 01-03-07) 
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Methodological considerations for statistical modeling 
Based on recent publications (Ezzati et al., 2002; Ezzati et al., 2003; Shibuya et al., 2003), 
we decided to model the impact of different interventions in burden of disease terms.  This 
procedure can be justified by the fact that for tobacco abuse1 – contrary to alcohol abuse 
and illicit drugs – the overwhelming majority of direct costs materializes in health care, see 
(Single et al., 1996; Single et al., 1998; Rehm et al., 2006).   
 
The usual epidemiological model as defined by burden of disease studies, especially on the 
international level (Murray & Lopez, 1996; Murray et al., 2000; WHO, 2001; WHO, 2002), 
operates with one-dimensional risk factors and foresees the following steps: 
• Estimation of disease-, sex- and age-specific population attributable fractions, in the 
case of tobacco estimation of smoking-attributable fractions (see formula below). 
• Based on smoking-attributable fractions, smoking-attributable deaths and disability 
adjusted life years (DALYs) via years of life lost due to disability (YLDs) and years of 
life lost due to mortality (YLLs). 
 
As you will see below, there is some discrepancy in the results of different methods for 
smoking-attributable mortality.  We used three different methods to estimate overall 
mortality, YLLs and DALYs.  In addition, we used two tracer diagnoses where there is much 
less variability: lung cancer and ischaemic heart disease (IHD; see Table Methods-1). 
                                                 
1  The term “abuse” here is used in the economical definition and does not necessarily effect the 
psychiatric definition of DSM-IV. 
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Table Methods-1:  Selected tracer diagnosis for epidemiological modeling 
Disease ICD-9 
Global burden 
of disease 
study Code 
ICD10 MTL 1 
codes ICD-10 
Ischaemic Heart Disease (IHD) 410-414 W107 1067 I20-I25 
Lung cancer 162 W067 1034 C33-C34 
 
The contribution of a risk factor to disease or mortality relative to some alternative exposure 
scenario (i.e. PAF, defined as the proportional reduction in population disease or mortality 
that would occur if exposure to the risk factor were reduced to an alternative exposure 
scenario, ceteris paribus (Miettinen, 1974; Eide & Heuch, 2001) is given by the generalized 
“potential impact fraction” in Equation 1, or its discrete version when exposure variable is 
categorical (Eide & Heuch, 2001; Walter, 1976; Walter, 1980). 
 
0 0
0
( ) ( ) ( ) ( )
( ) ( )
m m
x x
m
x
RR x P x dx RR x P x dx
PIF
RR x P x dx
= =
=
′−
=
∫ ∫
∫
      (1) 
RR(x):  relative risk at exposure level x 
P(x):  population distribution of exposure 
P′(x):  counterfactual distribution of exposure (often 0 = no exposure for tobacco) 
m:   maximum exposure level 
 
Because most diseases are caused by multiple risk factors, and because some risk factors 
act through other, more proximal, factors, population attributable fractions for multiple risk 
factors for the same disease can add up to more than 100% (Rothman, 1976; Rothman & 
Greenland, 1998).  For example, some of the cardiovascular disease events may be due to 
combination of smoking, physical inactivity and inadequate intake of fruits and vegetables 
(all acting partially through obesity, cholesterol, and blood pressure).  Such cases would be 
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attributed to all of these risk factors.  While lack of additivity may seem problematic initially, 
multiple causality offers opportunities to tailor prevention based on availability and cost of 
interventions.  In terms of tobacco interventions, this means that the projected mortality 
gains will be achieved through constellations in which some of the gains could also be 
achieved by other interventions; e.g. the mortality reduction of tobacco taxation on CHD 
could in part be achieved by improving physical fitness in the population.  
 
To estimate smoking-attributable mortality and burden of disease attributable fractions were 
calculated using the discrete version of Equation 1.   
 
 
Risk relations  
Direct approaches based on Relative Risk and prevalence 
As indicated by Equation 1, the calculation of smoking-attributable mortality was based on 
the combination of relative risks and prevalence of exposure.  The selection of tobacco-
related diseases and causes of death relied on recent comprehensive reviews by the 
International Agency for Research on Cancer (IARC, 2004) and the U.S. Government 
(USDHHS: U.S. Department of Health and Human Services, 2004).  The list of these 
conditions is reported in Table Methods-2.  
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Table Methods-2:  Conditions caused by tobacco smoking (English et al., 1995; 
IARC, 2004; USDHHS: U.S.Department of Health and Human 
Services, 2004) 
Cause of death  ICD 9  ICD10  
Lip, oral and pharyngeal cancer  140-149  C00- C14  
Esophageal cancer  150  C15  
Stomach cancer  151  C16  
Liver cancer  155  C22  
Pancreas cancer  157  C25  
Laryngeal cancer  161  C32  
Lung cancer  162  C33-C34  
Cervical cancer  180  C53  
Bladder cancer  188  C67  
Kidney, other urinary cancer  189  C64-C66, C68  
Leukemia  204-208  C92  
Parkinson disease  332  G20-G21  
Ischaemic heart disease  410-414  I20-I25  
Other heart diseases  390-398, 415-417, 420-429  I00-I09, I26-I51  
Cerebrovascular diseases  430-438  I60-I69  
Atherosclerosis  440  I70  
Other arterial diseases  441-448  I71-I78  
Pneumonia  480-487  J10-J18  
Bronchitis, emphysema  490-492  J40-J43  
COPD  490-492, 496  J40-J44  
Peptic ulcer  531-534  K25-K27  
Crohn’s disease  555  K50  
Ulcerative colitis  556  K51  
Fire injury  E890-E899  X00-X09  
 
 
Two sets of relative risks were used in the analysis.  The first set was derived from the 
Cancer Prevention Study II (CPS-II), a large prospective cohort study conducted by the 
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American Cancer Society (USDHHS: U.S. Department of Health and Human Services, 
2004).  Between 1982 and 1984 over one million healthy American volunteers were enrolled 
in the study; tobacco smoking was assessed at baseline.  Sex-specific relative risks for 
current and ex-smokers are listed in Table Methods-3.  For several tobacco-related 
conditions, no relative risks have been reported for CPS-II.  
 
Table Methods-3:  Relative Risks from Cancer Prevention Study II (CPS II) 
Relative risk  
Cause of death  ICD9 codes  
M-
current 
smokers 
M-
Former 
smokers 
W-
current 
smokers 
W-
Former 
smokers  
Comments  
Lip, oral and pharyngeal 
cancer  140-149  10.9  3.4  5.1  2.3  
 
Esophageal cancer  150  6.8  4.5  7.8  2.8   
Stomach cancer  151  2.0  1.5  1.4  1.3   
Liver cancer  155  NA  NA  NA  NA   
Pancreatic cancer  157  2.3  1.2  2.3  1.6   
Laryngeal cancer  161  14.6  6.3  13.0  5.2   
Lung cancer  162  23.3  8.7  12.7  4.5   
Cervical cancer  180  - - 1.6  1.1   
Bladder cancer  188  3.3  2.1  2.2  1.9   
Kidney, other urinary cancer  189  2.7  1.7  1.3  1.1   
Leukemia  204-208  1.9  1.3  1.1  1.4   
Parkinson disease*  332  0.69  0.79  0.6  0.9  Other source  
Ischaemic heart disease <65  410-414  2.8  1.6  3.1  1.3   
Ischaemic heart disease 65+  410-414  1.5  1.2  1.6  1.2   
Other heart diseases  
390-398, 
415-417, 
420-429  
1.8  1.2  1.5  1.1  
 
Cerebrovascular diseases 
<65  430-438  3.3  1.0  4.0  1.3  
 
Cerebrovascular diseases 
65+  430-438  1.6  1.0  1.5  1.0  
 
Atherosclerosis  440  2.4  1.3  1.8  1.0   
Other arterial diseases**  441-448  4.15  2.05  4.65  1.6  
Average of the 
RRs of the Aortic 
aneurysm and 
Other arterial 
disease  
Atherosclerosis and other 
arterial diseases  440-448  NA  NA  NA  NA  
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Pneumonia  480-487  1.8  1.4  2.2  1.1   
Bronchitis, emphysema  490-492  17.1  15.6  12.0  11.8   
Chronic airways obstruction  496  10.6  6.8  13.1  6.8   
COPD  490-492, 496  NA  NA  NA  NA  
 
Peptic ulcer  531-534  NA  NA  NA  NA   
Crohn’s disease  555  NA  NA  NA  NA   
Ulcerative colitis  556  NA  NA  NA  NA   
Fire injury  E890-E899  NA  NA  NA  NA  
 
 
The second set of relative risks was abstracted from a comprehensive review of 
determinants of health prepared by the Australian Government, which contained systematic 
meta-analyses of health effects of tobacco smoking (English et al., 1995).  These relative 
risks are listed in Table Methods-4: with a few exceptions, there was differentiation between 
risks for ex-smokers and current smokers, but relative risks were not sex-specific.  The 
categories of diseases did not fully overlap between the two sets of relative risks, but the 
main tobacco-related causes of death were included in both. 
 
Table Methods-4:  Relative Risks from English et al. (1995) 
English et al., 1995  
Cause of death  ICD9 codes  Former 
smokers 
Current 
smokers  
Comments  
Lip, oral and pharyngeal cancer  140-149  1.76  4.55  RRs for codes: 140-141, 143-149  
Esophageal cancer  150  1.79  4.01   
Stomach cancer  151  1.11  1.41   
Liver cancer  155  1.07  1.71   
Pancreatic cancer  157  1.15  1.86   
Laryngeal cancer  161  2.86  7.48   
Lung cancer - men  162  6.75  13.0   
Lung cancer – women  162  5.07  11.4   
Cervical cancer  180  1.31  1.75  RRs for codes: 180, 233.1  
Bladder cancer  188  1.66  2.72   
Kidney, other urinary cancer  189  1.61  1.64  Renal parenchymal carcinoma - 189.0  
Leukemia  204-208 1.21  1.01   
Parkinson disease  332  0.57  0.57   
Ischaemic heart disease <65  410-414  1.45  3.06   
Ischaemic heart disease-m. 65+  410-414  0.93  1.67   
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Ischaemic heart disease-w. 65+  410-414  1.22  1.67   
Other heart diseases  
390-398, 
415-417, 
420-429  
NA  NA  
 
Cerebrovascular disease <65  430-438  1.30  3.12   
Cerebrovascular disease 65+  430-438  1.15  1.65   
Atherosclerosis  440  NA  NA   
Other arterial diseases  441-448  NA  NA   
Atherosclerosis and other arterial 
diseases  440-448  1.82  2.54  
 
Pneumonia  480-487  1.29  1.47   
Bronchitis, emphysema  490-492  NA  NA   
Chronic airways obstruction  496  NA  NA   
COPD  490-492, 496  6.70  9.80  
 
Peptic ulcer  531-534  2.24  2.07   
Crohn’s disease - men  555  1.92  1.92   
Crohn’s disease - women  555  1.60  3.27   
Ulcerative colitis  556  1.71  0.63   
Fire injury  E890-E899  NA  NA  TAF = 23%  
 
The smoking-attributable mortality fractions were calculated by combining relative risks and 
exposure prevalence (see below; for a summary of RR used for the tracer diagnoses only 
see Appendix 2).  
 
Indirect approaches based on lung cancer mortality 
In addition to the direct epidemiological method described here, a third method was used, 
which is usually labelled “indirect” method or Peto-method (first described in Peto et al., 
1992).  Basically, this method stipulates, that all smoking-related mortality burden is based 
on the comparison of lung cancer mortality rates from the smoking-affected society under 
consideration (in our case Switzerland) with lung cancer mortality rates of a societal group 
not at al affected by smoking (a historical cohort of females in the US), deriving a so-called 
Smoking Impact Ratio.  In basing all estimates on lung cancer mortality as an indirect 
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measure of exposure, the Peto-method is able to capture a cumulative effect of exposure 
rather basing all calculations on a one shot cross-sectional picture of exposure. 
 
 
Effects of environmental tobacco smoke (ETS) 
The causal role of passive smoking for many diseases is still controversial.  Thus, this 
analysis adopted a conservative approach and included only two diseases for which the 
evidence converges, which were the same as our tracer diagnoses: lung cancer and IHD.  
Passive smoking-attributable mortality and morbidity traditionally would be derived by 
combining Relative Risks (RR) for passive smoking for lung cancer and ischaemic heart 
disease (IHD) with the age- and sex-specific prevalence rates of the population of Swiss 
who have never smoked, but are exposed to environmental tobacco smoke (ETS) from 
spouses and other sources inside the home.  However, the latter proportion was not known.  
Thus, we took the proportion of deaths from passive smoking to all other tobacco-related 
deaths from the Canadian cost study (Rehm et al., 2006), and applied this ratio to the Swiss 
results. 
 
The Canadian study used the following assumptions: passive smoking-attributable mortality 
(PSAM) was derived by combining age- and sex-specific RRs for lung cancer and IHD and 
the respective prevalence rates for Canada.  RR estimates were obtained from the most 
comprehensive meta-analyses: Taylor and colleagues (Taylor et al., 2001) derived a RR 
estimate of 1.21 for ETS for lung cancer; de Groh and Morrison (de Groh & Morrison, 2002); 
see also (Heloma & Jaakkola, 2003) used a RR estimate of 1.24 for IHD.  Both estimates 
are consistent with the results of other meta-analyses.  Zhong and colleagues (Zhong et al., 
2000) cited a RR estimate of 1.2 for lung cancer from a meta-analysis of 35 case-control 
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and 5 cohort studies.  The RR associated with exposure to environmental tobacco smoke for 
IHD was estimated from two recent meta-analyses.  Thun and colleagues (Thun et al., 1999) 
noted RRs of 1.24 for males and 1.23 for females exposed to passive smoking, while He 
and colleagues (He et al., 1999) estimated a RR of 1.25 for both sexes.  For reasons of 
comparability and conservatism, Baliunas and the team of the Canadian study (Baliunas et 
al., in press) used an RR estimate of 1.21 for lung cancer and an RR estimate of 1.24 for 
IHD.   
 
Based on these assumptions the following proportions between active and passive smoking-
attributable deaths could be found (Table Methods-5). 
 
Table Methods-5: Proportions between active and passive smoking-attributable 
deaths in Canada 2002 
 Men Women Total 
Total smoking-attributable deaths 23,766 13,443 37,209 
Total smoking-attributable deaths due to ETS 507 324 831 
ETS/total deaths without ETS 2.2% 2.5% 2.3% 
 
Smoking-attributable lung cancer deaths 9,028 4,373 13,401 
Smoking-attributable lung cancer deaths due to 
ETS 157 95 252 
ETS/total deaths without ETS (lung cancer) 1.8% 2.2% 1.9% 
 
Smoking-attributable IHD deaths 3,837 1,506 5,343 
Smoking-attributable IHD deaths due to ETS 350 228 578 
ETS/total deaths without ETS (IHD) 10.0% 17.8% 12.1% 
Numbers may not add up because of rounding (all numbers are based on attributable fractions and 
thus have decimals) 
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Assumptions on natural course of smoking 
For some of the epidemiological and economic calculations, current prevalence rates were 
not sufficient information, but additional information about the natural change of exposure 
was needed (i.e. when effectiveness of an intervention was given as an Odds Ratio 
compared to placebo or natural course).  In other words, we needed information about 
natural change for a society like Switzerland, where the political climate increasingly 
highlights the risk of tobacco exposure on health, both for the smoker and for second parties 
(i.e. the risks of second hand or environmental tobacco smoke). 
 
To perform these calculations, we first considered the comparison between the Swiss Health 
Surveys 1997 and 2002.  Overall, regular smoking prevalence rates decreased during this 
time period by 3.8 percentage points for males and by 2.3 percentage points for females 
(analysis by Swiss Health Observatory: www.obsan.ch/monitoring/statistiken/3-2-
1/2002/d/321.pdf ). 
 
Clearly, the comparison between 1997 and 2002 only reflects a trend of net prevalence 
rates, i.e. the net of the total of successful quitting efforts and the total of incidence of 
smoking plus the demographic changes.  Moreover, it is a rough approximation, as 
respondents were surveyed at a specific point in time, whereas smoking behaviour is a 
variable behaviour with the possibility of several status changes within one year even (e.g. 
several quitting attempts with only the last one being successful). 
 
Most importantly, however, the change in Switzerland between 1997 and 2002 may not 
reflect future changes.  At least in the first years after 1997, tobacco smoking in Switzerland 
was still considerably more accepted compared to North America or Australia.  It was also 
much more accepted behaviour then than it is now in Switzerland.  Thus natural course 
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assumptions in an unfavourable socio-cultural climate had to assume higher net rates of 
quitting than those realized between 1997 and 2002.   
 
As a consequence, in order to model smoking behaviour in a society with a socio-political 
climate exerting pressure towards reducing smoking rates, we assumed a scenario based 
on the literature as informed by trends observed in regions of North America and Australia 
featuring intense efforts to reduce tobacco related harm plus the experiences of Switzerland 
(e.g.  www.sfa-ispa.ch ; Tillgren et al., 1995; Bondy et al., 2000).  These scenarios were 
based on (see also Rehm et al., 2004b): 
• yearly quitting rates of 10%; 
• the assumption that 80% of smokers wanted to quit, 
• the assumption of an annual smoking initiation rate of 3% of the never smokers in 
the age groups between 15 and 44 years of age.  No initiation was assumed for the 
older age groups. 
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Results 
Exposure 
Exposure was taken from the Swiss Health Survey (S6B) 2002.  Details of this survey can 
be obtained from the website of the Swiss Federal Office of Statistics (www.bfs.admin.ch 
and www.statistik.admin.ch./stat-ch/ber14/dtfr14-s.htm). 
 
Table Results-1 and Figure-Results 1 give an overview of exposure to smoking by sex and 
age, Appendix 3 has more details. 
 
Table Results-1: Smoking categories in Switzerland 2002 
Smoking categories*   
Overall 
(All 
ages) 
15-19 
years 
20-44 
years 
45-64 
years 
65+ 
years 
Women 62.2% 70.3% 57.9% 56.4% 76.3% 
Never smokers 
Male 48.1% 68.5% 52.8% 38.8% 42.3% 
Women 16.2% 4.4% 14.3% 21.9% 15.7% 
Former smokers 
Male 23.9% 4.5% 13.5% 34.1% 42.9% 
Women 21.6% 25.4% 27.8% 21.7% 8.0% 
Current smokers 
Male 28.1% 27.0% 33.7% 27.2% 14.8% 
Women 100% 100% 100% 100% 100% 
Total 
Male 100% 100% 100% 100% 100% 
Source:  Swiss Health Survey 2002, calculations by G.Gmel 
Notes: Cigars (=5), cigarillos (=2.5), and pipes (=2.5) were converted into cigarette.  
  Table includes smokers of other tobacco products, not only cigarette smokers.  
  Smokers of less than 1 (converted cigarette) a day on average were coded as never 
smokers. 
 Current smokers are those with 1 or  more converted cigarettes per day on average; includes 
potential chippers who smoke only weekends but more than 6 cigarettes (converted) a week 
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Figure Results-1: Prevalence of different smoking categories by age and sex in 
Switzerland 2002  
Prevalence in percentage of different smoking categories in 
Switzerland in 2002
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 Source: Swiss Health Survey 2002, calculations by G.Gmel 
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Smoking-attributable mortality and burden of disease in 
Switzerland 2002 
Direct estimates of mortality based on English et al. (1995) Relative Risk 
information 
Table Results-2 gives an overview of smoking-attributable deaths in Switzerland for the year 
2002 based on the RR of (English et al., 1995), without accounting for environmental 
tobacco smoke.  Overall, 3224 male and 1482 female deaths in this year are estimated to be 
smoking-attributable according to this method. 
 
Table Results-2: Smoking-attributable deaths in Switzerland 2002 – direct 
estimates based on English et al. (1995) RR information 
Males 20-44 45-64 20-64 65+ 
Total 
20+ 
Tobacco-related deaths 85 1,141 1,227 2,968 4,194 
All deaths from all causes 1,498 5,094 6,592 22,750 29,342 
Percentage 5.70% 22.40% 18.61% 13.04% 14.29% 
      
Women 20-44 45-64 20-64 65+ 
Total 
20+ 
Tobacco-related deaths 36 402 438 1,404 1,843 
All deaths from all causes 734 2,906 3,640 28,137 31,777 
Percentage 4.95% 13.83% 12.04% 4.99% 5.80% 
      
      
Malignant neoplasms      
Males 20-44 45-64 20-64 65+ 
Total 
20+ 
(a) Tobacco-related deaths from malignant neoplasms 35 709 743 1,462 2,205 
(b) All deaths from malignant neoplasms 175 1,995 2,170 6,165 8,335 
Percentage (a)/(b) 19.81% 35.53% 34.26% 23.71% 26.46% 
(c) All deaths from all causes 1,498 5,094 6,592 22,750 29,342 
Percentage (a)/(c) 2.31% 13.91% 11.28% 6.43% 7.52% 
      
Women 20-44 45-64 20-64 65+ 
Total 
20+ 
(a) Tobacco-related deaths from malignant neoplasms 23 270 293 416 709 
(b) All deaths from malignant neoplasms 223 1,586 1,809 5,032 6,841 
Percentage (a)/(b) 10.31% 17.02% 16.19% 8.26% 10.36% 
(c) All deaths from all causes 734 2,906 3,640 28,137 31,777 
Percentage (a)/(c) 3.13% 9.29% 8.05% 1.48% 2.23% 
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Cardiovascular diseases      
Males 20-44 45-64 20-64 65+ 
Total 
20+ 
(a) Tobacco-related deaths from cardiovascular 
diseases 43 331 374 488 862 
(b) All deaths from cardiovascular diseases 182 1,209 1,391 9,025 10,416 
Percentage (a)/(b) 23.64% 27.35% 26.87% 5.41% 8.28% 
(c) All deaths from all causes 1,498 5,094 6,592 22,750 29,342 
Percentage (a)/(c) 2.87% 6.49% 5.67% 2.15% 2.94% 
      
Women 20-44 45-64 20-64 65+ 
Total 
20+ 
(a) Tobacco-related deaths from cardiovascular 
diseases 12 85 97 578 675 
(b) All deaths from cardiovascular diseases 63 408 471 12,836 13,307 
Percentage (a)/(b) 18.48% 20.93% 20.60% 4.50% 5.07% 
(c) All deaths from all causes 734 2,906 3,640 28,137 31,777 
Percentage (a)/(c) 1.59% 2.94% 2.67% 2.05% 2.12% 
Numbers may not add up because of rounding (all numbers are based on attributable fractions and 
thus have decimals) 
 
Direct estimates of mortality based on CPS II Relative Risk information 
Table Results-3 gives an overview of smoking-attributable deaths in Switzerland for the year 
2002 based on the RR of CPS II, again without accounting for environmental tobacco 
smoke.  Overall, 4308 male and 1663 female deaths in the year 2002 are estimated to be 
smoking-attributable. 
 
Table Results-3: Smoking-attributable deaths in Switzerland 2002 – direct 
estimates based on CPS II RR information 
Males 20-44 45-64 20-64 65+ 
Total 
20+ 
Tobacco-related deaths 111 1,312 1,422 3,917 5,339 
All deaths from all causes 1498 5,094 6,592 22,750 29,342 
Percentage 7.38% 25.75% 21.58% 17.22% 18.20% 
      
Women 20-44 45-64 20-64 65+ 
Total 
20+ 
Tobacco-related deaths 43 437 480 1,586 2,066 
All deaths from all causes 734 2,906 3,640 28,137 31,777 
Percentage 5.80% 15.04% 13.18% 5.64% 6.50% 
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Malignant neoplasms      
Males 20-44 45-64 20-64 65+ 
Total 
20+ 
(a) Tobacco-related deaths from malignant neoplasms 45 821 866 1,698 25,65 
(b) All deaths from malignant neoplasms 175 1,995 2,170 6,165 8,335 
Percentage (a)/(b) 25.58% 41.17% 39.92% 27.55% 30.77% 
(c) All deaths from all causes 1,498 5,094 6,592 22,750 29,342 
Percentage (a)/(c) 2.99% 16.13% 13.14% 7.47% 8.74% 
      
Women 20-44 45-64 20-64 65+ 
Total 
20+ 
(a) Tobacco-related deaths from malignant neoplasms 25 286 311 469 779 
(b) All deaths from malignant neoplasms 223 1,586 1,809 5,032 6,841 
Percentage (a)/(b) 11.00% 18.04% 17.17% 9.31% 11.39% 
(c) All deaths from all causes 734 2906 3640 28137 31777 
Percentage (a)/(c) 3.34% 9.84% 8.53% 1.67% 2.45% 
      
      
Cardiovascular diseases      
Males 20-44 45-64 20-64 65+ 
Total 
20+ 
(a) Tobacco-related deaths from cardiovascular 
diseases 58 388 447 1,126 1,573 
(b) All deaths from cardiovascular diseases 182 1,209 1,391 9,025 10,416 
Percentage (a)/(b) 32.10% 32.13% 32.13% 12.48% 15.10% 
(c) All deaths from all causes 1,498 5,094 6,592 22,750 29,342 
Percentage (a)/(c) 3.90% 7.63% 6.78% 4.95% 5.36% 
      
Women 20-44 45-64 20-64 65+ 
Total 
20+ 
(a) Tobacco-related deaths from cardiovascular 
diseases 16 104 119 664 783 
(b) All deaths from cardiovascular diseases 63 408 471 12,836 13,307 
Percentage (a)/(b) 25.06% 25.40% 25.35% 5.17% 5.89% 
(c) All deaths from all causes 734 2,906 3,640 28,137 31,777 
Percentage (a)/(c) 2.15% 3.57% 3.28% 2.36% 2.46% 
Numbers may not add up because of rounding (all numbers are based on attributable fractions and 
thus have decimals) 
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Comparison of direct mortality estimates based on different RRs 
In the following graphs, both methods are compared with respect to their results.  Overall, 
the CPS II method gives higher smoking-attributable deaths, especially for men (see Figure 
Results-2). 
 
 
Figure Results-2: Comparison of smoking-attributable deaths in Switzerland 2002 – 
based on English et al., 1995 versus CPS II-RR information 
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Figure Results-3: Comparison of smoking-attributable deaths of malignant 
neoplasms in Switzerland 2002 –  
(English et al., 1995) versus CPS II RR information 
0
500
1000
1500
2000
2500
3000
20-44 45-64 65+ Total 20+
de
at
hs
Men English
Men CPS II
Women English
Women CPS II
 
 
These differences are about the same for smoking-related neoplasms (see Figure Results-
3), where the estimates of both methods are relatively close to each other, but the CPS II 
method was on average about 15% higher than the English et al. (1995) estimate. 
 
For the second largest disease category, cardiovascular disease, there are significant 
differences (overall more than 50% greater for CPS II), mainly in the oldest age group.  This 
difference is based to a large degree on a residual category of “other heart disease”, i.e. not 
in the two main categories of IHD and cerebrovascular disease. 
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Figure Results-4: Comparison of smoking-attributable cardiovascular deaths in 
Switzerland 2002 –  
English et al. (1995) versus CPS II RR information 
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Given both estimates and the results of the comparison, we decided to use the more 
conservative methods of direct estimation, as it was based on a range of studies in different 
countries, thereby reducing potential biases.  Also, it did not include residual categories such 
as “other heart disease”. 
 
 
Indirect estimates of mortality 
Based on the indirect method of Peto described above, 7,300 people were estimated to be 
killed in 2000 (the closest year where data with estimates from the Peto method are 
available).  As expected in a country where the smoking rate has been declining, this 
method, which is based on cumulative exposure, yielded higher smoking-attributable 
mortality (see Figure Results-5). 
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Figure Results-5: Smoking-attributable mortality based on indirect method (Peto et 
al., 1992; Peto et al., 2006)  
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Tracer diagnoses 
The two tracer diagnoses of IHD and lung cancer made up the majority of smoking-
attributable deaths.  Using (English et al., 1995) RR, we estimated that about half of the 
overall smoking-attributable mortality was accounted for by these two diagnoses alone, and 
in proportions that were approximately equal for both sexes  (51.7% of smoking-attributable 
deaths in men, 52.7% in women, and 52.07% overall; see overview Table Results-4).  Thus, 
the use of these two diagnoses as tracer diagnoses was valid. 
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Table Results-4: Smoking-attributable IHD and lung cancer deaths in Switzerland 2002 – direct estimates based on (English et al., 
1995)  
Smoking-
attributable 
fraction 
Smoking-attributable deaths 
Overall (all ages) 20-44 Yrs 45-64 Yrs 65+ Yrs Total 
Cause of death 
ICD10 
MTL 1 
codes 
M W        M W M W M W M W M & W
Lung cancer 1,034 81.8% 65.8% 17 16 462 207 1,102 286 1,581 510 2,091 
Ischaemic heart 
disease 1,067   11.9% 9.0% 30 5 284 55 271 401 585 461 1,046
Numbers may not add up because of rounding (all numbers are based on attributable fractions and thus have decimals) 
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Estimating all smoking-attributable deaths including the effects of 
environmental tobacco smoke (ETS) 
So far, for direct methods we have only considered the effects of smoking for the smokers 
themselves.  In the following, we will estimate the effects of environmental tobacco smoke in 
order to estimate the total number of smoking-attributable deaths.  In order to do so, we would 
need the prevalence rates of people exposed to smoke and the respective relative risks for this.  
However, in the Swiss Health Survey, these rates were not available.  As an alternative, we 
used the ratio of deaths from indirect exposure (=ETS) vs. direct exposure in Canada (Rehm et 
al., 2006; Baliunas et al., in press).  These numbers are based on the Canadian rates of 
exposure to environmental tobacco smoke, and the Relative Risks for this exposure, as derived 
from meta-analyses (de Groh & Morrison, 2002; He et al., 1999; Taylor et al., 2001; Zhong et 
al., 2000; further details see above). 
 
Using these assumptions, the following numbers of smoking-attributable deaths for Switzerland 
could be estimated (see Results Table-5). 
 
Table Results-5: Estimates of smoking-attributable deaths in Switzerland 2002 
including ETS 
 Men Women Total % of all deaths 
Total smoking-attributable deaths from own smoking  
(English et al., 1995 – direct method) 4,194 1,843 6,037 9.9%
Total smoking-attributable deaths from own smoking  
(CPS II – indirect method) 5,339 1,663 7,002 11.5%
ETS/total deaths without ETS (from Canada) 2.2% 2.5% 2.3%  
ETS (English et al., 1995 – direct method) 91 46 138 0.2%
ETS (CPS II – direct method) 116 41 160 0.3%
Total smoking-attributable deaths  
(English et al., 1995) direct method 4,286 1,888 6,175 10.1%
Total smoking-attributable deaths (CPS II – direct method) 5,455 1,704 7,162 11.8%
Total smoking-attributable deaths  
(Peto et al., 1992; Peto et al., 2006) – indirect method 5,600 1,800 7,300 12.0%
Numbers may not add up because of rounding (all numbers are based on attributable fractions and thus 
have decimals); the numbers of Peto et al. (2006) are based on the year 2000, and were given in 100 in 
the original publication. 
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The main results shows that between 6,175 and 7,300 smoking-attributable deaths could be 
estimated form Switzerland for 2002.  This corresponds to a rate between 10% and 12% of all 
of the deaths in Switzerland in this year. 
 
 
Smoking-attributable years of life lost (YLLs) 
Based on the methods of the CRA described above (see also Ezzati et al., 2002; Ezzati et al., 
2004; Rehm & Frick, 2004), the smoking-attributable years of life lost (YLLs) for the year 2002 
were calculated (see Table Results-6).  These YLLs were estimated based on the most 
conservative estimate with the underlying RR from English and colleagues (English et al., 
1995). 
 
Table Results-6: Smoking-attributable YLLs in Switzerland 2002 
Diagnosis Gender Total % of all YLLs 
Total 
including ETS 
% of all 
YLLs 
M 11,812 82.7% 12,069 84.5% 
W 4,684 71.5% 4,800 73.3% Lung cancer 
Total 16,496 79.2% 16,869 81.0% 
M 6,108 20.7% 6,241 21.2% 
W 2,486 15.4% 2,547 15.8% IHD 
Total 8,594 18.8% 8,788 19.3% 
M 31,471 15.2% 32,157 15.5% 
W 11,431 7.9% 11,714 8.1% All cause 
Total 42,902 12.2% 43,871 12.5% 
Numbers may not add up because of rounding (all numbers are based on attributable fractions and thus 
have decimals) 
 
Overall, over 40 thousand YLLs were caused by smoking in 2002 in Switzerland, corresponding 
to about 12.5% of all of the YLLs in this time period. 
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Smoking-attributable burden of disease 
The smoking-attributable burden of disease from the same year is summarized in Table 
Results-7.  Overall, slightly less than 60 thousand DALYs were caused by tobacco.  This 
corresponds to 7.6% of the total burden of disease in Switzerland, indicating that smoking-
related categories of disease are quite lethal rather than disabling. 
 
Table Results-7: Burden of disease (DALYs) estimates of smoking-attributable in 
Switzerland 2002 
Diagnosis Gender Total %of all DALYs 
Total 
including ETS 
%of all 
DALYs 
M 12,211 82.7% 12,477 84.5% 
W 4,843 71.6% 4,963 73.4% Lung cancer 
Total 17,054 79.2% 17,440 81.0% 
M 7,210 22.4% 7,367 22.9% 
W 2,938 16.8% 3,011 17.2% IHD 
Total 10,148 20.4% 10,378 20.9% 
M 41,439 9.8% 42,342 10.1% 
W 17,834 4.7% 18,274 4.8% All cause 
Total 59,273 7.4% 60,617 7.6% 
Numbers may not add up because of rounding (all numbers are based on attributable fractions and thus 
have decimals) 
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Effectiveness of tobacco control interventions 
Underlying data 
The following Table Results-8 gives a summary of the effectiveness of the selected 
interventions. 
 
Table Results-8: Interventions and their effectiveness 
Type of intervention Effect Reference 
Public policy interventions 
Taxation and price increases 
2% prevalence reduction in smokers 
associated with 10% increase in price, 
based on meta-analysis for high income 
countries. 
(Ranson et al., 2000)  
Interventions for preventing 
tobacco smoking in public places 
Effective policy as demonstrated by 
reduction of smoking in public places.  
However, the overall impact on 
prevalence of smoking is not clear. 
(Serra et al., 2000)  
Workplace interventions for 
smoking cessation. 
Lack of evidence that comprehensive 
workplace programs reduced the 
prevalence of smoking.  All effects were 
based on known effects of individual 
therapy and counselling, which are 
modeled separately here. 
(Moher et al., 2003)  
Interventions focusing on individual behavioural change (counselling, brief advice, therapy) 
Individual behavioural 
counselling for smoking 
cessation (non-medical) 
Cessation ratio of 1.56 (95% CI: 1.32 – 
1.84) compared to controls without 
intervention 
(Lancaster & Stead, 
2005)  Individual 
behavioural counselling 
for smoking cessation. 
Nicotine replacement therapy for 
smoking cessation 
Cessation ratio of 1.77 (95% CI: 1.66 – 
1.88) compared to controls without 
intervention; modeled here with and 
without medical advice. 
(Silagy et al., 2004)  
Physician advice for smoking 
cessation 
Cessation ratio of 1.74 (95% CI: 1.48 – 
2.05) compared to controls without 
intervention 
(Lancaster & Stead, 
2004)  
 
 
Effectiveness with respect to prevalence rates 
Table Results-9 translates these effects into the common metric of smoking prevalence in the 
Swiss adult population (operationalized as all inhabitants 15 years and older).  More details can 
be found in Appendix 4. 
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Table Results-9: Interventions and their impact on number of smokers 
 Overall (all ages >15 ) Population affected 
Change to baseline in 
reduction of numbers of 
smokers 
 M W M W M W Total 
Population in 
thousand 2860.332 3108.618      
Natural course plus quitters plus new beginners = baseline scenario 
Current smokers 26.77% 20.79% 765.784 646.269 0 0 0
Taxation 
Current smokers 26.24% 20.37% 750.468 633.344 -15.316 -12.925 -28.241
Smoking ban at public places 
Current smokers 26.50% 20.58% 758.126 639.807 -7.658 -6.463 -14.121
Comprehensive workplace program in addition to individual measures 
Current smokers 26.77% 20.79% 765.784 646.269 0 0 0
Individual behavioural counselling (assuming 40% coverage*) 
Current smokers 26.14% 20.30% 747.745 631.194 -18.039 -15.076 -33.115
NRT (assuming 40% coverage*) 
Current smokers 25.91% 20.12% 740.980 625.541 -24.804 -20.729 -45.533
Physician's advice (assuming 40% coverage*) 
Current smokers 25.94% 20.15% 741.947 626.348 -23.837 -19.921 -43.759
NRT plus taxation plus ban of smoking in public spaces (assuming 40% coverage*) 
Current smokers 25.16% 19.54% 719.688 607.558 -46.096 -38.712 -84.807
* All coverage rates are based on the overall population willing to quit (80%) 
 
 
The results show that based on the situation in 2002 more than 80,000 smokers in Switzerland 
would quit smoking, if three interventions could be implemented: 
• an increase in taxation resulting in a price increase of 10%; 
• wider availability and application of nicotine replacement therapy; 
• a ban of smoking in public places. 
 
Effectiveness with respect to health outcomes 
The next Tables show the effectiveness of interventions on health outcomes (Table Results-10 
for all-cause smoking-attributable mortality, Table Results-11 for the two tracer diagnosis; see 
also Appendix 5 for details). 
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Table Results-10: Interventions and their impact on smoking-attributable deaths (all cause), 15+ years in Switzerland, 2002 
All cause mortality Men Women Total 
Natural course plus quitters plus new 
beginners = baseline scenario  4,119  1,808  5,927 
Smoking-attributable deaths 
saved 
Smoking-attributable deaths 
saved including ETS Various Intervention Scenarios   
Men Women Total Men Women Total 
Taxation change to result in price 
increases of 10%  4,105          1,794  5,900 13 13 27 14 14 27
Smoking ban at public places  4,111  1,802  5,914 7 5 13 8 6 13 
Comprehensive workplace program in 
addition to individual measures  4,119         
         
         
         
 1,808  5,927 0 0 0 0 0 0
Individual behavioural counselling 
(assuming 40% coverage based on 
those willing to quit) 
 4,099  1,796  5,896 19 11 31 20 12 31
NRT (assuming 40% coverage based 
on those willing to quit)  4,093  1,788  5,881 26 19 45 27 20 46
Physician's advice (assuming 40% 
coverage based on those willing to quit)  4,093  1,788  5,881 26 19 46 27 20 47
NRT plus taxation plus ban of smoking 
in public spaces (assuming 40% 
coverage based on those willing to quit) 
 4,067  1,776  5,844 52 31 83 53 32 85 
Numbers may not add up because of rounding (all numbers are based on attributable fractions and thus have decimals) 
All scenarios are based on the prevalence figures displayed in Table Results-9. 
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Table Results-11: Interventions and their impact on smoking-attributable IHD and lung cancer deaths, 15+ years 
in Switzerland, 2002 
Ischaemic Heart Disease (IHD) Men Women Total 
Natural course plus quitters plus new 
beginners = baseline scenario 
543   447 991
Smoking-attributable deaths saved Smoking-attributable deaths saved including ETS Various Intervention Scenarios  
Men Women Total Men Women Total 
Taxation change to result in price 
increases of 10% 
535         
         
         
         
         
         
442 8 5 13 9 6 15
Smoking ban at public places 539 445 984 4 2 6 4 3 7
Comprehensive workplace program in 
addition to individual measures 
543 447 991 0 0 0 0 0 0
Individual behavioural counselling 
(assuming 40% coverage based on those 
willing to quit) 
533 443 975 11 4 15 12 5 17
NRT (assuming 40% coverage based on 
those willing to quit) 
529 440 969 15 7 22 16 9 25
Physician's advice (assuming 40% 
coverage based on those willing to quit) 
529 440 969 15 7 22 16 9 25
NRT plus taxation plus ban of smoking in 
public spaces (assuming 40% coverage 
based on those willing to quit) 
515 435 950 29 12 41 32 14 46 
977
Numbers may not add up because of rounding (all numbers are based on attributable fractions and thus have decimals) 
All scenarios are based on the prevalence figures displayed in Table Results-9. 
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Table Results-11 cont: 
Lung cancer Men Women Total 
Natural course plus quitters plus new 
beginners = baseline scenario 1,575   505 2,080
Smoking-attributable deaths saved Smoking-attributable deaths saved including ETS Various Intervention Scenarios  
Men Women Total Men Women Total 
Taxation change to result in price 
increases of 10% 1,575        503 2,078 1 2 3 1 2 3
Smoking ban at public places 1,575 504 2,079 1 1 1 1 1 1 
Comprehensive workplace program in 
addition to individual measures 1,575        
        
        
        
505 2,080 0 0 0 0 0 0
Individual behavioural counselling 
(assuming 40% coverage based on those 
willing to quit) 
1,574 503 2,077 1 2 3 1 2 3
NRT (assuming 40% coverage based on 
those willing to quit) 1,573 502 2,076 2 3 5 2 3 5
Physician's advice (assuming 40% 
coverage based on those willing to quit) 1,573 502 2,076 2 3 5 2 3 5
NRT plus taxation plus ban of smoking in 
public spaces (assuming 40% coverage 
based on those willing to quit) 
1,571 501 2,072 4 4 8 4 5 8 
Numbers may not add up because of rounding (all numbers are based on attributable fractions and thus have decimals) 
All scenarios are based on the prevalence figures displayed in Table Results-9. 
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The different calculations show, that progress can be made with respect to reducing prevalence 
of smoking and subsequently with reducing smoking-attributable mortality.  However, the 
burden will be continue to be substantial even after implementing more than one of the chosen 
interventions.  Thus even if Switzerland increases taxation to result in a 10% price increase plus 
installs a ban of smoking in public places plus implements NRT for 40% of those wishing to quit, 
the overall smoking prevalence would still be around 20%, and less than 100 deaths would be 
saved annually, a large part in IHD.  And given the long latency period between smoking and 
smoking-related mortality, many of the consequences of the high smoking rates of the 
immediate past and today will only be seen in decades from now.  Thus, more drastic measures 
may be considered to reduce prevalence rates earlier.  The following sensitivity analyses will 
look at the potential consequences of such more drastic strategies. 
 
 
Sensitivity analysis with more marked taxation increases 
Tables Results-12 and 13 show the impact of two more marked taxation changes, resulting in a 
50% respectively 100% increase of price for cigarettes, both for smoking prevalence rates 
(Table Results-12) and health outcome (Table Results-13).  Clearly these drastic taxation 
changes would result in more pronounced changes.  For instance, a 100% increase of price 
would result in 20% reduction of smoking prevalence and 272 deaths saved per year (see Table 
Results 13). 
: 
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Table Results-12: More marked taxation increases and their impact on smoking-attributable prevalence 
Sensitivity scenario1: taxation to increase price by 50%  
All ages >15 0-14 Yrs 15-19 Yrs 20-44 Yrs 45-64 Yrs 65+ Yrs 
 M W      M W M W M W M W M W
Never smokers 47.01%            61.27% 100.0% 100.0% 66.4% 68.2% 51.2% 56.2% 38.8% 56.4% 42.3% 76.3%
Former smokers 28.89%            20.02% 0.0% 0.0% 9.4% 8.9% 19.5% 19.2% 38.7% 25.6% 45.5% 17.0%
Current smokers 24.10%            18.71% 0.0% 0.0% 24.2% 22.9% 29.3% 24.6% 22.5% 18.0% 12.3% 6.6%
Total 100.00%           100.00% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Change of smoking 
prevalence to baseline -2.68%            -2.08% 0.00% 0.00% -2.69% -2.54% -3.26% -2.73% -2.50% -2.00% -1.36% -0.74%
Sensitivity scenario2: taxation to increase price by 100%  
All ages >15 0-14 Yrs 15-19 Yrs 20-44 Yrs 45-64 Yrs 65+ Yrs 
 M W      M W M W M W M W M W
Never smokers 47.01%            61.27% 100.0% 100.0% 66.4% 68.2% 51.2% 56.2% 38.8% 56.4% 42.3% 76.3%
Former smokers 31.57%            22.10% 0.0% 0.0% 12.0% 11.5% 22.8% 22.0% 41.2% 27.6% 46.8% 17.8%
Current smokers 21.42%            16.63% 0.0% 0.0% 21.5% 20.3% 26.1% 21.9% 20.0% 16.0% 10.9% 5.9%
Total 100.00%           100.00% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Change of smoking 
prevalence to baseline -5.35%            -4.16% 0.00% 0.00% -5.39% -5.09% -6.52% -5.46% -5.00% -3.99% -2.73% -1.48%
 
46 
Cost effectiveness tobacco  47 
Table Results-13:  More marked taxation increases and their impact on health outcomes 
All cause Men Women Total 
Natural course plus quitters plus new 
beginners = baseline scenario 4,119   1,808 5,927
Smoking-attributable deaths 
saved 
Smoking-attributable deaths 
saved including ETS Tax Related Intervention Scenarios  
Men    
         
Women Total Men  Women Total
Taxation change to result in price 
increases of 50% 4,033 1,763 5,796 86 44 131 88 45 133
Taxation change to result in price 
increases of 100% 3,942         1,719 5,661 177 88 265 181 91 272
Ischaemic Heart Disease (IHD) Men Women Total 
Natural course plus quitters plus new 
beginners = baseline scenario 543   447 991
Smoking-attributable deaths 
saved 
Smoking-attributable deaths 
saved including ETS Tax Related Intervention Scenarios  
Men    
         
Women Total Men  Women Total
Taxation change to result in price 
increases of 50% 495 430 926 48 17 65 53 20 73
Taxation change to result in price 
increases of 100% 445         414 859 99 34 132 108 40 148
Lung cancer Men Women Total 
Natural course plus quitters plus new 
beginners = baseline scenario 1,575   505 2,080
Smoking-attributable deaths 
saved 
Smoking-attributable deaths 
saved including ETS Tax Related Intervention Scenarios  
Men    
        
Women Total Men  Women Total
Taxation change to result in price 
increases of 50% 1,569 499 2,067 7 6 13 7 7 13
Taxation change to result in price 
increases of 100% 1,562         492 2,054 14 13 27 14 13 27
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Cost-effectiveness of tobacco control interventions 
Table Results-14 summarizes the main results of this study with respect to effectiveness and 
cost-effectiveness of the interventions analysed. 
 
Table Results-14:  Summary table on effectiveness, costs and cost-effectiveness of 
different interventions for reducing smoking-attributable harm 
Effectiveness Costs* Cost-effectiveness Various 
intervention 
scenarios for 
tobacco control 
% of 
smokers 
reduced 
Deaths 
saved in CHF 
Cost per 1% 
reduction of 
smokers 
Cost per avoided 
death 
Taxation change to 
result in price 
increases of 10% 
-2.0% 27 2,791,047 1,395,526 101,700 
Smoking ban at public 
places -1.0% 13 5,765,358 5,765,166 436,195 
Comprehensive 
workplace program in 
addition to individual 
measures 
0.0% 0 
irrelevant 
because of 
lack of 
effectiveness 
irrelevant 
because of 
lack of 
effectiveness 
 not applicable 
Individual behavioural 
counselling (assuming 
40% coverage based 
on those willing to 
quit) 
-2.3% 31 23,414,676 9,984,226 743,772 
NRT (assuming 40% 
coverage based on 
those willing to quit) – 
baseline scenario 
(medication cost only) 
-3.2% 46 235,707,740 73,096,836  5,083,290 
NRT (assuming 40% 
coverage based on 
those willing to quit) 
-3.2% 46 259,122,417 80,358,111 5,588,252 
Physician's advice 
(assuming 40% 
coverage based on 
those willing to quit) 
-3.1% 47 23,414,676 7,555,649 501,925 
NRT plus taxation plus 
ban of smoking in 
public spaces 
(assuming 40% 
coverage based on 
those willing to quit) 
-6.0% 85 267,678,821 44,569,043 3,158,968 
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Table Results-14:  
Sensitivity analyses 
Taxation change to 
result in price 
increases of 50% 
-10.0% 133 2,791,047 279,105 20,910 
Taxation change to 
result in price 
increases of 100% 
-20.0% 272 2,791,047 139,552 10,279 
* Assumptions in deriving cost estimates will be given in the text. 
 
The cost estimates were derived as follows:  the costs of the public health interventions were 
taken from the WHO Choice Databank for Euro A, with a conversion rate of I$ (for a definition of  
international $ see http://www.who.int/choice/costs/ppp/en/index.html) to CHF for 2002 of 1.80 
(for rate see http://www.oecd.org/dataoecd/61/56/1876133.xls; last accessed on 01-12-07; for 
other publications on cost-effectiveness of different interventions for tobacco control using this 
approach to costing see: Shibuya et al., 2003; Chisholm et al., 2006).   
 
The costs for the individual interventions are based on the calculations summarized in Appendix 
6 and the following assumptions: 
¾ individual counselling: based on an intervention of up to 15 minutes by a trained 
psychologist; 
¾ physicians’ advice: based on an intervention of up to 15 minutes 
¾ NRT: base scenario includes cost of medication only; second scenario includes costs for 
prescribing and medication (for the latter see Cornuz et al., 1994). 
¾ No additional costs are assumed for more marked taxation increases compared to the 
base increase resulting in a price increase of 10%, even though there may be more 
costs for enforcement, resulting from more smuggling. 
 
Man results indicate that with respect to cost-effectiveness, public policy measures such as 
even minor increases in taxation or ban of smoking in public places clearly are more cost-
effective than individual counselling or therapy.  Of course, the cost-effectiveness ratio becomes 
even more favourable for more drastic taxation increases.  For instance, the costs for reduction 
of smoking prevalence by 1% vary between CHF 140,000 (drastic taxation increases which 
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double the price for cigarettes) and more than CHF 80 millions, if prevalence is reduced by 
prescribed nicotine replacement therapy alone.  This indicates that effective public policy 
measures should be sought whenever feasible.  Otherwise, society will pay a huge price for 
even moderate reductions in smoking-related harm. 
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Relevance 
Smoking-attributable mortality and burden of disease is a major public health problem in 
Switzerland.  There are effective evidence-based interventions which could also be 
implemented here.  However, these interventions will bring only gradual improvements in 
reducing prevalence of smoking and smoking-attributable burden of disease, and individual-
based interventions such as counselling and therapy will be associated with a rather high cost 
to society.  Given this situation, more drastic public policy measures than currently 
contemplated should be considered.  Such measures should be especially considered in light of 
the recent experiences, when public policy measures such as a ban in all restaurants were 
implemented successfully in European countries such as Italy with public support, even though 
critics have long warned that such measures are unthinkable in such cultures. 
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Appendix 1: Cover letter and list interventions 
 
Name Adresse 
 
 
 
 Zürich, 16.01.06 
 
Sehr geehrte(r) .... 
Im Rahmen einer vergleichenden Analyse der Kosteneffektivität evidenzbasierter 
Massnahmen zur Verringerung der Tabak-bedingten Mortalität in der Schweiz führt 
das ISGF eine Studie durch, in deren Rahmen wir die wichtigsten Methoden gegen den 
Tabakmissbrauch für die Schweiz identifizieren wollen, um deren Kosten-Effektivität zu prüfen. 
Dafür bedürfen wir Ihrer Hilfe!  
Ich möchten Sie höflich bitten, sich zwei Minuten Zeit zu nehmen, um uns folgende Fragen zu 
beantworten: 
 
 
i
 
1. Welche fünf der beigelegten Interventionsmethoden stellen nach Ihrer 
Erfahrung  für die Schweiz die wichtigsten Massnahmen gegen die 
Tabakmissbrauch dar? Bitte ankreuzen.
2. Welche Interventionsmethoden, die für die Schweiz wichtig s nd, fehlen in 
dieser Liste? 
Für Ihre Unterstützung bedanke ich mich herzlich im Voraus und verbleibe  
 
mit freundlichen Grüßen 
 
Domenic Schnoz 
Institut für Sucht- und Gesundheitsforschung 
Tel. 044 / 448 11 79  
Email: domenic.schnoz@isgf.unizh.ch 
 
Beilage: 
- Liste:  Methoden / Massnahmen gegen Tabakmissbrauch in der Schweiz 
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METHODEN/MASSNAHMEN GEGEN TABAKMISSBRAUCH IN DER SCHWEIZ 
(Bitte markieren Sie die fünf wichtigsten Methoden mit einem „X“) 
 
___• Akupunktur 
___• Antidepressiva 
___• Anxiolytikum 
___• Aversives Rauchen 
___• Clonidine 
___• Gemeinschaftliche Intervention 
___• Intervention von gemeinschaftlichem pharmazeutischem Personal 
___• Wettbewerbe und Anreize 
___• Förderung der Unterstützung durch den Partner 
___• Übungs-Interventionen 
___• Rauchen-Kontroll-Programme für Familie und Betreuer 
___• Gruppenverhalten-Therapie-Programme 
___• Gesundheitspflege-Finanzierungs-Systeme um die Benützung von Tabak-
Abhängigkeits-Behandlungen zu erhöhen 
___• Schlaftherapie 
___• Individuelle Verhaltensberatungen 
___• Interventionen für voroperatives Beenden des Rauchens 
___• Interventionen um den Verkauf von Tabak an Minderjährige zu verhindern 
___• Interventionen um das Tabakrauchen auf öffentlichen Plätzen zu verhindern 
___• Interventionen um rauchlosen Tabakkonsum zu beenden 
___• Interventionen um das Rauchen bei hospitalisierten Patienten zu beenden 
___• Lobeline 
___• Massenmediale Interventionen 
___• Mecamylamine 
___• Nikotin-Ersatz-Therapie 
___• Krankenpflegerische Interventionen 
___• Opioid-Antagonisten 
___• Ärztlicher Rat 
___• Aufhören-und-Gewinnnen-Wettbewerbe 
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___• Rückfall-Verhinderungs-Interventionen 
___• Schulbasierte Programme 
___• Selbsthilfe-Interventionen 
___• Silberacetat 
___• Telefonberatung 
___• Training für Gesundheits-Spezialisten 
___• Arbeitsplatz-Interventionen 
•       Andere:_________________________________________________ 
    _________________________________________________ 
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Appendix 2: Summary of RR used for tracer diagnoses 
Relative risks and 95% confidence intervals (CI) for tracer diagnoses lung cancer and IHD 
Current Smokers 
(Cigarettes per Day) Sex Age Ex-smokers 
Any 
  RR          95% CI RR          95% CI 
Lung cancer 
M All 6.75  (6.16-7.40) 13.0  (12.2-13.7) 
F All 5.07  (4.66-5.51) 11.4  (10.5-12.3) 
IHD 
Age <65 years 
M+F  All 1.45    (1.41-1.50) 3.06    (3.00-3.13) 
Age 65+ years 
M+F All 1.12    (1.07-1.16) 1.66    (1.59-1.74) 
M All 0.93    (0.87-1.00) 1.67    (1.54-1.82) 
F All 1.22    (1.16-1.29) 1.67    (1.58-1.77) 
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Appendix 3: Smoking in Switzerland by age and sex – Swiss Health Survey 2002 
SMOKING CATEGORIES BY GENDER, SWITZERLAND 2002        
Age groups 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 
Current smokers 27.04 39.20 33.87 33.14 33.38 30.65 29.85 31.91 23.98 20.97
Ex-smokers   4.50 3.97 7.93 15.11 14.65 21.42 28.56 31.87 40.56 36.71
Never smokers   68.46 56.83 58.20 51.75 51.97 47.94 41.58 36.22 35.46 42.33M
A
L
E
S
 
Total   100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Age groups   15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 
Current smokers 25.35 31.51 24.60 25.29 27.37 30.44 25.33 23.26 21.73 15.05
Ex-smokers   4.37 6.73 12.06 12.70 18.10 18.92 22.70 22.36 22.68 19.39
Never smokers   70.28 61.76 63.34 62.01 54.53 50.64 51.97 54.37 55.59 65.56
W
O
M
E
N
 
Total   100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
         
Age groups  65-69 70-74 75-79 80-84 85+ TOTAL 
Current smokers  20.98 15.56 8.91 12.01 8.64 28.08
Ex-smokers   42.00 42.00 43.28 49.47 38.60 23.87
Never smokers 
 
  37.02 42.44 47.81 38.52 52.76 48.05M
A
L
E
S
 
Total   100.00 100.00 100.00 100.00 100.00 100.00
Age groups   65-69 70-74 75-79 80-84 85+ TOTAL 
Current smokers  14.48 8.58 5.38 5.86 2.05 21.64
Ex-smokers   17.53 16.62 17.02 9.84 14.94 16.19
Never smokers 
 
  67.99 74.80 77.60 84.30 83.01 62.17
W
O
M
E
N
 
Total   100.00 100.00 100.00 100.00 100.00 100.00  
Source:  Swiss Health Survey 2002, calculations by G.Gmel 
Notes: Cigars (=5), cigarillos (=2.5), and pipes (=2.5) were converted into cigarette.  
  Table includes smokers of other tobacco products, not only cigarette smokers.  
  Smokers of less than 1 (converted cigarette) a day on average were coded as never smokers. 
 Current smokers are those with 1 or more converted cigarettes per day on average; includes potential chippers who smoke only weekends but more than 
6 cigarettes (converted) a week 
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Detailed categories of smoking in Switzerland 2002: Women 
(Swiss Health Survey; analyses by SFA, 2004) 
Age groups (AG) Smoking 
category (SC) 15-29 30-44 45-59 60-69 70-79 80+ 
Total 
Nonsmoker        
Count 368,161 464,705 367,536 231,296 265,542 115,523 1,812,763
% within SC 20.3% 25.6% 20.3% 12.8% 14.6% 6.4% 100.0%
% within AG 58.8% 51.5% 50.5% 65.0% 74.9% 82.6% 58.4%
Ex-smoker   
Count 47,695 149,191 164,345 65,807 59,577 16,327 502,942
% within SC 9.5% 29.7% 32.7% 13.1% 11.8% 3.2% 100.0%
% within AG 7.6% 16.5% 22.6% 18.5% 16.8% 11.7% 16.2%
Smoking 0-14 
cigarettes per day   
Count 153,348 168,725 115,733 33,498 20,720 5,947 497,971
% within SC 30.8% 33.9% 23.2% 6.7% 4.2% 1.2% 100.0%
% within AG 24.5% 18.7% 15.9% 9.4% 5.8% 4.3% 16.0%
Smoking 15 plus 
cigarettes per day   
Count 56,413 120,227 80,354 24,992 8,918 2,060 292,964
% within SC 19.3% 41.0% 27.4% 8.5% 3.0% .7% 100.0%
% within AG 9.0% 13.3% 11.0% 7.0% 2.5% 1.5% 9.4%
All Women   
Count 625,617 902,848 727,968 355,593 354,757 139,857 3,106,640
% within SC 20.1% 29.1% 23.4% 11.4% 11.4% 4.5% 100.0%
 
Cost effectiveness tobacco  61 
 
Detailed categories of smoking in Switzerland 2002: Men 
(Swiss Health Survey; analyses by SFA, 2004) 
Age groups (AG) Smoking 
category (SC) 15-29 30-44 45-59 60-69 70-79 80+ 
Total 
Nonsmoker        
Count 334,048 392,857 214,896 103,637 92,420 30,290 1,168,148
% within SC 28.6% 33.6% 18.4% 8.9% 7.9% 2.6% 100.0%
% within AG 53.0% 43.1% 29.4% 32.1% 40.2% 37.4% 40.2%
Ex-smoker   
Count 34,332 154,408 244,659 125,886 97,796 37,259 694,340
% within SC 4.9% 22.2% 35.2% 18.1% 14.1% 5.4% 100.0%
% within AG 5.4% 16.9% 33.4% 39.0% 42.5% 46.0% 23.9%
Smoking 0-14 
cigarettes per day   
Count 170,248 186,783 137,306 58,770 27,296 10,453 590,856
% within SC 28.8% 31.6% 23.2% 9.9% 4.6% 1.8% 100.0%
% within AG 27.0% 20.5% 18.8% 18.2% 11.9% 12.9% 20.3%
Smoking 15 plus 
cigarettes per day   
Count 91,853 178,507 135,089 34,116 12,327 3,003 454,895
% within SC 20.2% 39.2% 29.7% 7.5% 2.7% .7% 100.0%
% within AG 14.6% 19.6% 18.5% 10.6% 5.4% 3.7% 15.6%
All males   
Count 630,481 912,555 731,950 322,409 229,839 81,005 2,908,239
% within SC 21.7% 31.4% 25.2% 11.1% 7.9% 2.8% 100.0%
 
 
Cost effectiveness tobacco  62 
Appendix 4: Detailed results of effectiveness of different interventions for smoking 
cessation on prevalence of smoking 
  Overall (all ages >15 ) 0-14 Yrs 15-19 Yrs 20-44 Yrs 45-64 Yrs 65+ Yrs 
  M F M F M F M F M F M F 
Population in 
thousand 2860.332  3108.618 635.878 605.145 214.09 209.581 1294.448 1304.801 899.07 944.661 452.724 649.575 
% 100.0%  100.0% 7.5% 6.7% 45.3% 42.0% 31.4% 30.4% 15.8% 20.9% 
Never 
smokers 47.89%  62.14% 100.0% 100.0% 68.5% 70.3% 52.8% 57.9% 38.8% 56.4% 42.3% 76.3% 
Former 
smokers 23.96%  16.21% 0.0% 0.0% 4.5% 4.4% 13.5% 14.3% 34.1% 21.9% 42.9% 15.7% 
Current 
smokers 28.15%  21.65% 0.0% 0.0% 27.0% 25.4% 33.7% 27.8% 27.2% 21.7% 14.8% 8.0% 
Natural course plus quitters 
Never 
smokers 47.88%  62.14% 100.0% 100.0% 68.5% 70.3% 52.8% 57.9% 38.8% 56.4% 42.3% 76.3% 
Former 
smokers 26.22%  17.94% 0.0% 0.0% 6.7% 6.4% 16.2% 16.5% 36.2% 23.6% 44.1% 16.3% 
Current 
smokers 25.90%  19.92% 0.0% 0.0% 24.9% 23.3% 31.0% 25.6% 25.0% 20.0% 13.6% 7.4% 
  100.00%  100.00% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
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Appendix 4 cont. 
  Overall (all ages >15 ) 0-14 Yrs 15-19 Yrs 20-44 Yrs 45-64 Yrs 65+ Yrs 
  M F M F M F M F M F M F 
Natural course plus quitters plus new beginners = baseline scenario 
Never 
smokers 47.01%  61.27% 100.0% 100.0% 66.4% 68.2% 51.2% 56.2% 38.8% 56.4% 42.3% 76.3% 
Former 
smokers 26.22%  17.94% 0.0% 0.0% 6.7% 6.4% 16.2% 16.5% 36.2% 23.6% 44.1% 16.3% 
Current 
smokers 26.77%  20.79% 0.0% 0.0% 26.9% 25.4% 32.6% 27.3% 25.0% 20.0% 13.6% 7.4% 
100.00% 100.00% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
Taxation change to result in price increases of 10% 
Never 
smokers 47.01%  61.27% 100.0% 100.0% 66.4% 68.2% 51.2% 56.2% 38.8% 56.4% 42.3% 76.3% 
Former 
smokers 26.75%  18.36% 0.0% 0.0% 7.2% 6.9% 16.9% 17.0% 36.7% 24.0% 44.4% 16.4% 
Current 
smokers 26.24%  20.37% 0.0% 0.0% 26.4% 24.9% 31.9% 26.8% 24.5% 19.6% 13.4% 7.2% 
100.00% 100.00% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
Smoking ban at public places 
Never 
smokers 47.01%  61.27% 100.0% 100.0% 66.4% 68.2% 51.2% 56.2% 38.8% 56.4% 42.3% 76.3% 
Former 
smokers 26.48%  18.15% 0.0% 0.0% 6.9% 6.7% 16.6% 16.8% 36.5% 23.8% 44.2% 16.4% 
Current 
smokers 26.50%  20.58% 0.0% 0.0% 26.7% 25.2% 32.3% 27.0% 24.7% 19.8% 13.5% 7.3% 
100.00% 100.00% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
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Appendix 4 cont. 
  Overall (all ages >15 ) 0-14 Yrs 15-19 Yrs 20-44 Yrs 45-64 Yrs 65+ Yrs 
  M F M F M F M F M F M F 
Comprehensive workplace program in addition to individual measures 
Never 
smokers 47.01%  61.27% 100.0% 100.0% 66.4% 68.2% 51.2% 56.2% 38.8% 56.4% 42.3% 76.3% 
Former 
smokers 26.22%  17.94% 0.0% 0.0% 6.7% 6.4% 16.2% 16.5% 36.2% 23.6% 44.1% 16.3% 
Current 
smokers 26.77%  20.79% 0.0% 0.0% 26.9% 25.4% 32.6% 27.3% 25.0% 20.0% 13.6% 7.4% 
100.00% 100.00% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
Individual behavioural counselling (assuming 40% coverage based on those willing to quit) 
Never 
smokers 47.01%  61.27% 100.0% 100.0% 66.4% 68.2% 51.2% 56.2% 38.8% 56.4% 42.3% 76.3% 
Former 
smokers 26.85%  18.43% 0.0% 0.0% 7.3% 7.0% 17.0% 17.1% 36.9% 24.1% 44.4% 16.5% 
Current 
smokers 26.14%  20.30% 0.0% 0.0% 26.3% 24.9% 31.8% 26.7% 24.4% 19.5% 13.3% 7.2% 
100.00% 100.00% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
NRT (assuming 40% coverage based on those willing to quit) 
Never 
smokers 47.01%  61.27% 100.0% 100.0% 66.4% 68.2% 51.2% 56.2% 38.8% 56.4% 42.3% 76.3% 
Former 
smokers 27.08%  18.61% 0.0% 0.0% 7.5% 7.2% 17.3% 17.4% 37.1% 24.3% 44.5% 16.5% 
Current 
smokers 25.91%  20.12% 0.0% 0.0% 26.1% 24.6% 31.5% 26.5% 24.2% 19.3% 13.2% 7.1% 
100.00% 100.00% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
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Appendix 4 cont. 
  Overall (all ages >15 ) 0-14 Yrs 15-19 Yrs 20-44 Yrs 45-64 Yrs 65+ Yrs 
  M F M F M F M F M F M F 
physician's advice (assuming 40% coverage based on those willing to quit) 
Never 
smokers 47.01%  61.27% 100.0% 100.0% 66.4% 68.2% 51.2% 56.2% 38.8% 56.4% 42.3% 76.3% 
Former 
smokers 27.05%  18.58% 0.0% 0.0% 7.5% 7.1% 17.2% 17.3% 37.0% 24.3% 44.5% 16.5% 
Current 
smokers 25.94%  20.15% 0.0% 0.0% 26.1% 24.7% 31.6% 26.5% 24.2% 19.3% 13.2% 7.1% 
100.00% 100.00% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
NRT plus taxation plus ban of smoking in public spaces (assuming 40% coverage based on those willing to quit) 
Never 
smokers 47.01%  61.27% 100.0% 100.0% 66.4% 68.2% 51.2% 56.2% 38.8% 56.4% 42.3% 76.3% 
Former 
smokers 27.83%  19.19% 0.0% 0.0% 8.2% 7.9% 18.2% 18.1% 37.8% 24.9% 44.9% 16.7% 
Current 
smokers 25.16%  19.54% 0.0% 0.0% 25.3% 23.9% 30.6% 25.7% 23.5% 18.7% 12.8% 6.9% 
100.00% 100.00% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
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Appendix 5: Detailed results of effectiveness of different interventions for 
smoking cessation on mortality 
20-44 Yrs 45-64 Yrs 65+ Yrs 20+ Yrs   - - - All cause 
Men Women Men Women Men Women Men Women Total - - - 
Natural course plus quitters plus new 
beginners = baseline scenario 
85      36 1,123 395 2,911 1,376 4,119 1,808 5,927 - - -
Smoking-attributable deaths 
saved Various Intervention Scenarios   
   
        
 
Men Women Total
Taxation change to result in price 
increases of 10% 
84 36 1,118 393 2,903 1,365 4,105 1,794 5,900 13 13 27
Smoking ban at public places 85            
      
        
        
        
        
36 1,120 2,907 1,372 4,111 1,802 5,914 7 5 13
Comprehensive workplace program in 
addition to individual measures 
85 36 1,123 395 2,911 1,376 4,119 1,808 5,927 0 0 0
Individual behavioural counseling 
(assuming 40% coverage based on 
those willing to quit) 
84 36 1,118 393 2,898 1,367 4,099 1,796 5,896 19 11 31
NRT (assuming 40% coverage based 
on those willing to quit) 
84 36 1,116 392 2,893 1,360 4,093 1,788 5,881 26 19 45
Physician's advice (assuming 40% 
coverage based on those willing to quit) 
84 36 1,115 392 2,893 1,360 4,093 1,788 5,881 26 19 46
NRT plus taxation plus ban of smoking 
in public spaces (assuming 40% 
coverage based on those willing to quit) 
83 36 1,109 389 2,874 1,351 4,067 1,776 5,844 52 31 83
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Appendix 6: Costs in Switzerland for personal 
interventions 
Preise von medizinischen Leistungen in der Schweiz im 
Jahre 2002 im Rahmen der Rauchentwöhnungstherapie 
 
Kompiliert von Till A. Boluarte (Universität Witten Herdecke) und Domenic 
Schnoz (ISGF) 
 
 
Eine Stunde Hausarzt CH für das Jahr 2002 
 
Beratung zwischen 7 und 20 Uhr (bis zu einer 
Viertelstunde Dauer) 
 
6 TP pro 15 Min 
 
Pro Stunde = 24 TP 
 
TP Wert = 4.95 CHF (seit 01.07.1992 bis 31.12.2003) 
 
Verdienst Hausarzt pro Stunde = 118.80 CHF 
 
Quellen:  
Ambulante Tarife Spitalleistungskatalog (1992–2003), Zentralstelle für 
Medizinaltarife UVG (letzte Überarbeitung 31. Januar 1997) 
Aktuelle Taxpunktwerte (TPW) für UV/MV/IV-Patienten (Stand 01.01.2006), 
Zentralstelle für Medizinaltarife UVG 
 
 
Eine Stunde Psychologe CH 2002 
 
Leistungen durch klinische Psychologen/Psychotherapeuten 
(mit Hochschulabschluss und Ausbildung 
in Psychopathologie) 
 
Nichtärztliche psychologische Diagnostik und Therapie in der Psychiatrie, 
Einzelsetting 
 
6 TP pro 15 Min 
 
Pro Stunde = 24 TP 
 
TP Wert = 4.95 CHF (seit 01.07.1992 bis 31.12.2003) 
 
Verdienst Psychologe pro Stunde = 118.80 CHF 
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Quellen:  
Ambulante Tarife Spitalleistungskatalog (1992–2003), Zentralstelle für 
Medizinaltarife UVG (letzte Überarbeitung 31. Januar 1997) 
Aktuelle Taxpunktwerte (TPW) für UV/MV/IV-Patienten (Stand 01.01.2006), 
Zentralstelle für Medizinaltarife UVG 
 
 
Eine Stunde Sozialarbeiter CH 2002 
 
Leistungen durch nichtärztliches Personal (z.B. 
Psychiatrie-PflegerInnen unter ärztlicher 
Anordnung und Überwachung): 
 
„Die Behandlungen erfolgen durch von der Institution / Spitalabteilung 
angestelltem, nichtärztlichem Personal (Psychiatrieschwestern und 
Psychiatriepfleger sowie sozialtherapeutisches Personal wie Sozialpädagogen 
und Sozialarbeiter mit Zusatzausbildung, dipl. Psychologen und weiteres 
therapeutisch tätiges, nicht ärztliches Personal mit adäquater Ausbildung). „ 
– TARMED 2006 
 
Einzelbehandlung, pro volle oder angebrochene 
Viertelstunde 
 
4 TP pro 15 Min 
 
Pro Stunde = 16 TP 
 
TP Wert = 4.95 CHF (seit 01.07.1992 bis 31.12.2003) 
 
Verdienst Sozialarbeiter pro Stunde = 79,20 CHF 
 
Quellen:  
Ambulante Tarife Spitalleistungskatalog (1992–2003), Zentralstelle für 
Medizinaltarife UVG (letzte Überarbeitung 31. Januar 1997) 
Aktuelle Taxpunktwerte (TPW) für UV/MV/IV-Patienten (Stand 01.01.2006), 
Zentralstelle für Medizinaltarife UVG 
TARMED-Version 1.03, TARMED Suisse 
 
 
Preis für gängigsten Nikotinersatzstoff für 3 Monate (CH 2002) 
 
Sämtliche Leitlinien der Fachgesellschaften empfehlen die 
Nikotinersatztherapie, die vorwiegend mit Nikotinpflaster durchgeführt wird. 
 
Das Nikotinpflaster eignet sich sehr gut zu ökonomischen Berechnungen, da 
jeweils ein Pflaster pro 24 Stunden benötigt wird.  
 
Sowohl die Leitlinien der Dt. Ges. f. Suchtforschung und Suchttherapie (DG-
Sucht) und der Dt. Ges. f. Psychiatrie, Psychotherapie und Nervenheilkunde 
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(DGPPN), sowie die der amerikanischen Fachgesellschaften, ebenso wie 
Publikationen zum Thema „Rauchentwöhnung“ empfehlen für die Nikotin-
Ersatztherapie einen Zeitraum von bis zu drei Monaten (Cornuz et al. 
2003,2006 & Fiore 2000). 
 
Die „Arzneimittel-Fachinformation“ für Nicotinell® - Pflaster empfiehlt 
folgendes Therapie-Schema für starke Raucher:  
 
Wirkstärke des Pflasters Dauer der Anwendung 
Stark Beginnend für 4 Wochen 
Mittel Für weitere 4 Wochen 
Leicht Für weitere 4 Wochen 
Insgesamt: 12 Wochen Therapie 
 
 
Der Preis für diesen Zeitraum setzt sich nun wie folgt zusammen: 
 
Arzneimittel Zeitraum Packungsgröße Preis 
Nicotinell® 
Pflaster  
Stärke 1 (stark) 
21 mg/24 h 
 
4 Wochen 1 x 21 Stück + 
1 x 7 Stück 
129.70 CHF+ 
  50.25 CHF 
Nicotinell® 
Pflaster  
Stärke 2 (mittel) 
14 mg/24 h 
 
4 Wochen 1 x 21 Stück + 
1 x 7 Stück 
119.70 CHF+ 
  46.35 CHF 
Nicotinell® 
Pflaster  
Stärke 3 (leicht) 
7 mg/24 h 
 
4 Wochen 1 x 21 Stück + 
1 x 7 Stück 
109.75 CHF+ 
  42.55 CHF 
Gesamtpreis für 3 Monate Nikotinersatztherapie 
im Jahr 2002: 
498,30 CHF 
 
Da « Compendium Suisse des Médicaments » im Internet jeweils nur die 
aktuellen Preise publiziert. Wurde bei Documed (www.documed.ch) 
telefonische nachgefragt, ob die entsprechenden Preise aus dem Jahre 2002 
übermittelt werden können. Diese lieferten ein FAX, mit einer Kopie aus dem 
entsprechenden Datenmaterial aus dem Jahre 2002. 
 
 
Quellen: 
Cornuz J et al., Cost-effectiveness of pharmacotherapies for nicotine 
dependence in primary care settings: a multinational comparison, Tob. 
Control 2006;15;152-159  
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